Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS
· Delayed Price · Currency is USD
24.45
-1.55 (-5.96%)
Dec 23, 2024, 3:00 PM EST
TKPHF Revenue
Takeda Pharmaceutical Company had revenue of 1.18T JPY in the quarter ending September 30, 2024, with 12.75% growth. This brings the company's revenue in the last twelve months to 4.55T, up 9.43% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical Company had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,546.08B JPY
Revenue Growth
+9.43%
P/S Ratio
n/a
Revenue / Employee
92.25M JPY
Employees
49,281
Market Cap
41.44B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Takeda Pharmaceutical Company News
- 12 days ago - Takeda Pharmaceutical Co Ltd (TAK) Unveils Promising Late-Stage Pipeline at Investor R&D Day - GuruFocus
- 12 days ago - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas - Business Wire
- 17 days ago - Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors - Seeking Alpha
- 21 days ago - Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst - Benzinga
- 21 days ago - Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst - Benzinga
- 21 days ago - Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Business Wire
- 4 weeks ago - Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Business Wire
- 5 weeks ago - Why this major drugmaker no longer has an ‘IT department’ - Fortune